| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K34222889 | CTRPv2 | pan-cancer | AAC | -0.027 | 0.4 |
| mRNA | isoevodiamine | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | myricetin | CTRPv2 | pan-cancer | AAC | 0.032 | 0.4 |
| mRNA | SMER-3 | CTRPv2 | pan-cancer | AAC | 0.032 | 0.4 |
| mRNA | YK 4-279 | CTRPv2 | pan-cancer | AAC | -0.027 | 0.4 |
| mRNA | BRD1812 | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | ABT-888 | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.027 | 0.4 |
| mRNA | CIL41 | CTRPv2 | pan-cancer | AAC | 0.043 | 0.4 |